Vivani Medical Provides Business Update and Reports Second Quarter 2024 Financial Results
Vivani Medical Provides Update on Clinical Development Plans for Miniature, Long-term, GLP-1 Obesity Implant Program, NPM-115
Vivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for NPM-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant
Following in EU regulators' footsteps, the U.K. has reportedly launched a probe into potential suicide risks for popular diabetes and weight-loss drugs.
AstraZeneca`s once-weekly diabetes drug gets U.S. nod for children
Production constraints affecting diabetes treatment Bydureon Bcise dragged on revenue at AstraZeneca’s biopharmaceuticals business unit.
Elliot Ehrich, M.D., who capped an 18-year career at Alkermes in January, has joined Expansion Therapeutics as its chief medical officer. The company closed a $55.3 million series A round in January to advance a pipeline targeting disease-driving RNAs.
Xconomy Indiana — Eli Lilly has a blockbuster diabetes drug, dulaglutide (Trulicity), which helps the body make more insulin. But that drug, and others in the same class, are injectables. A number of companies are trying to offer patients a pill alternative.
AstraZeneca says the European Commission has approved a new formulation of its once-weekly diabetes drug Bydureon.
GLP-1 (glucagon-like peptide-1) receptor agonists make up a well-established class of treatment for Type 2 diabetes. AstraZeneca’s Byetta and Bydureon, Novo Nordisk’s Victoza and Ozempic, and Eli Lilly’s Trulicity all belong to this family. Because of their possible actions on nerve cells, scientists are now exploring the potential of GLP-1 receptor agonists in treating neurodegenerative diseases.